Xilio Therapeutics Inc

+0.18 (+5.88%)
Earnings Announcements

Xilio Therapeutics Reports Pipeline And Business Highlights And First Quarter 2022 Financial Results

Published: 05/12/2022 11:39 GMT
Xilio Therapeutics Inc (XLO) - Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results.
Cash Runway Anticipated Into First Half of 2024.
On Track With Plans to Submit Ind for Xtx301, a Tumor-selective Il-12, in Second Half of 2022.
Qtrly Loss per Share $0.78.
Q1 Earnings per Share View $-0.93 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.78

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.80

More details on our Analysts Page.